Astrazeneca Plc Stock Price, News & Analysis

AstraZeneca and Daiichi Sankyo announced positive Phase III trial results for ENHERTU in treating high-risk HER2-positive early-stage breast cancer. The DESTINY-Breast11 trial demonstrated that ENHERTU followed by THP showed a statistically significant improvement in pathologic complete response (pCR) rate compared to standard treatment. The trial also revealed an improved safety profile versus standard of care, with early positive trends in event-free survival. This marks the first Phase III trial showing ENHERTU's benefit in early breast cancer, potentially challenging current treatment standards. The safety profile was consistent with known data, and interstitial lung disease rates were similar across treatment arms. Notably, approximately one in three patients with early-stage breast cancer are considered high risk, and nearly half of patients receiving current neoadjuvant treatment do not achieve pCR.

AstraZeneca and Daiichi Sankyo announced positive Phase 3 trial results for ENHERTU® in treating high-risk HER2-positive early-stage breast cancer. The DESTINY-Breast11 trial demonstrated that ENHERTU followed by THP showed a statistically significant improvement in pathologic complete response (pCR) compared to standard treatment when used before surgery. The study revealed an improved safety profile versus standard care, with similar rates of interstitial lung disease across treatment arms. Early event-free survival data showed a positive trend favoring ENHERTU. This marks the first Phase 3 trial demonstrating ENHERTU's benefit in early breast cancer, potentially challenging current treatment standards. Approximately one-third of early-stage breast cancer patients are considered high-risk, with current treatments achieving pCR in only about half of patients.

AstraZeneca's BREZTRI AEROSPHERE achieved significant success in Phase III KALOS and LOGOS trials for uncontrolled asthma treatment. The trials demonstrated statistically significant and clinically meaningful improvement in lung function compared to dual-combination ICS/LABA medicines. The study included approximately 4,400 randomized patients, evaluating BREZTRI's 320/28.8/9.6μg dose. This development is particularly significant as 262 million people worldwide are affected by asthma, with nearly half of those on dual therapy remaining uncontrolled. BREZTRI, already approved for COPD treatment in over 80 countries, showed no new safety or tolerability concerns during these trials. The positive results position BREZTRI as a potential new treatment option for asthma patients who remain uncontrolled with current dual maintenance therapy.

AstraZeneca reported strong Q1 2025 financial results with total revenue up 10% to $13,588 million. The growth was driven by double-digit performance in Oncology and BioPharmaceuticals across all major regions. Core EPS increased 21% to $2.49, while reported EPS rose 34% to $1.88.

The quarter saw five positive Phase III readouts and 13 approvals in major regions. Key clinical successes included DESTINY-Breast09 for Enhertu, SERENA-6 for camizestrant, and MATTERHORN for Imfinzi. The company maintains its 2025 guidance, expecting high single-digit revenue growth and low double-digit Core EPS growth.

Strategic developments include the acquisition of EsoBiotec for up to $1 billion, FibroGen China purchase for $160 million, and establishment of a new R&D center in Beijing. The company is progressing toward its 2030 ambition of $80 billion in Total Revenue, supported by eleven US production sites and planned investments in manufacturing and R&D.

Puma Biotechnology presented clinical data for neratinib at the AACR Annual Meeting 2025 in Chicago. The Phase I trial (NCI 10495) evaluated the combination of neratinib with trastuzumab deruxtecan in patients with HER2-altered solid tumors.

Key findings from the 20-patient trial:

• Most common side effects: nausea (75%), diarrhea (75%), fatigue (65%)
• 4 patients achieved partial responses, including cases of gastroesophageal, pancreatic, and ovarian cancers
• Notable results in pancreatic cancer: 3 of 5 patients showed tumor shrinkage

The study established Dose Level 3 as the recommended Phase II dose: trastuzumab deruxtecan at 5.4 mg/kg combined with neratinib starting at 120 mg (week 1), increasing to 160 mg (week 2), and 240 mg (week 3 onward). Part 2 of the study, focusing on pharmacodynamic evaluation in 12 patients, began enrollment in March 2025.

SOPHiA GENETICS and AstraZeneca are expanding their collaboration to accelerate global liquid biopsy testing deployment. The partnership will extend MSK-ACCESS powered with SOPHiA DDM to 30 clinical institutions worldwide in 2025.

Key highlights:

• The liquid biopsy test detects genomic alterations from a single blood draw using advanced algorithms to analyze circulating tumor DNA
• This testing method offers advantages when traditional tissue biopsies are impractical due to cost, time, or invasiveness
• New data presented at AACR shows consistent accuracy across different laboratory settings

The expanded rollout supports AstraZeneca's real-world evidence initiatives and aims to validate decentralized liquid biopsy testing's clinical impact. The collaboration addresses a major industry challenge, as site-to-site result consistency has historically limited liquid biopsy adoption. Recent study results confirm the test maintains high analytical performance across multiple centers, matching the original standards set at Memorial Sloan Kettering Cancer Center.

Tempus AI (NASDAQ: TEM) has announced multi-year strategic collaborations with AstraZeneca and Pathos AI to develop the largest multimodal foundation model in oncology. The partnerships will focus on:

• Gathering biological and clinical insights
• Discovering novel drug targets
• Developing therapeutics for the oncology community

The agreements include $200 million in data licensing and model development fees to Tempus. The collaboration expands on Tempus' existing 2021 partnership with AstraZeneca, utilizing Tempus' AI-enabled platform and multimodal data repository to advance therapeutic programs in oncology globally. The foundation model will be built using Tempus' de-identified oncology data and will be shared among all three parties to enhance their respective patient care initiatives.

ENHERTU in combination with pertuzumab has shown highly significant improvement in progression-free survival (PFS) compared to current first-line standard treatment (taxane, trastuzumab and pertuzumab - THP) for HER2-positive metastatic breast cancer patients in the DESTINY-Breast09 Phase III trial.

This marks the first trial in over a decade demonstrating superior efficacy across broad HER2-positive metastatic breast cancer population versus current standard care. The PFS improvement was observed across all pre-specified patient subgroups. While overall survival data wasn't mature, early trends favor the ENHERTU combination.

HER2-positive metastatic breast cancer affects 15-20% of metastatic breast cancer patients. Despite current treatments, most patients experience disease progression within two years of first-line THP treatment, with approximately one-third never receiving second-line therapy due to progression or death.

AstraZeneca (AZN) and Daiichi Sankyo reported positive topline results from the DESTINY-Breast09 phase 3 trial, showing ENHERTU combined with pertuzumab significantly improved progression-free survival compared to current standard treatment in first-line HER2 positive metastatic breast cancer patients.

The trial demonstrated superior efficacy across all pre-specified patient subgroups. While overall survival data was not mature, early trends favor the ENHERTU combination. This marks the first trial in over a decade showing superior efficacy versus the current first-line standard of care for broad HER2 positive metastatic breast cancer patients.

HER2 positive metastatic breast cancer affects 15-20% of metastatic breast cancer patients, with most experiencing disease progression within two years of first-line treatment. The safety profile of ENHERTU with pertuzumab aligned with known profiles of each therapy. Regulatory submissions are now underway.